ThomasNet Home   |   Promote Your Business
Home  |   My ThomasNet News®  |   Industry Market Trends  |   Submit Release  |   Advertise  |   About Us May 24, 2012  

50 Pharma Companies Worldwide Now Use Codexis In Process Development

Print | 
Email |  Comment   Share  

Codexis, Inc.
200 Penobscot Drive
Redwood City,, CA, 94063,
USA



Press release date: October 24, 2011

Codexis Manufacturing Network Supports Pharma Customers from Development to Commercial Production

FRANKFURT, Germany - Codexis, Inc. (Nasdaq: CDXS) today announced that one year after launch, its Codex® Screening Kits are in use or evaluation in manufacturing process development at 50 pharmaceutical companies worldwide. The announcement was made at CPhI Worldwide, a global pharmaceutical ingredients convention meeting here this week.

Codex® Screening Kits were introduced in October 2010. Pharmaceutical and fine chemical companies including Merck, Roche, DSM and Dainippon Sumitomo are among the global customers using Codex® Screening Kits and Codex® Panels to reduce pharmaceutical manufacturing process development time and cost.

Codexis also said that through September 30, 2011, more than 10,000 kilograms of various enzymes used in commercial pharmaceutical intermediates production processes have been manufactured by the company's enzyme production partners. Smaller 10-100 kilogram quantities, also used in processes to make commercial pharmaceutical intermediates, have been manufactured at its Redwood City, CA facility.

"With a global network of production capabilities established, we are supporting our pharmaceutical and fine chemical customers at every scale, from clinical development to commercial production. This further demonstrates the utility of Codexis biocatalyst enzymes for the development and commercial production of pharmaceutical products," said Peter Strumph, Senior Vice President and Business Head, Pharmaceuticals.

Codexis is an industrial biotechnology company developing products that make manufacturing processes faster, cleaner and cheaper. Codexis' technology is commercialized with leading global pharmaceutical companies and is in development for advanced biofuels with Shell and for biobased chemicals. For more information, visit www.codexis.com.

Contacts:
Media: Lyn Christenson, lyn.christenson@codexis.com, 650.421.8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212.827.3771

SOURCE
Codexis, Inc.

Web Site: http://www.codexis.com

Print | 
Email |  Comment   Share  
Contacts: View detailed contact information.


 

Post a comment about this story

Name:
E-mail:
(your e-mail address will not be posted)
Comment title:
Comment:
To submit comment, enter the security code shown below and press 'Post Comment'.
 



 See related product stories
More .....
Don’t hunt for stories like this.
Let Product News Come to You!
Get a Free Subscription
to Product News Alerts.
Edit Story Categories
Start Your Free
Subscription to
Industry Market Trends.
 See more product news in:
Health, Medical and Dental Supplies and Equipment
Materials and Material Processing
 More New Product News from this company:
Research Tool facilitates safe drug development.
Biocatalyst Panels target phamaceutical industry.
Enzyme Panels facilitate biocatalyst development.
More ....
 Other News from this company:
Codexis, Raizen to Develop First Generation Ethanol
Codexis Presents Carbon Capture Update at DoE/NETL Conference
Codexis Announces First Cellulase Enzyme Scale up
Codexis to Present at the Jefferies and Pacific Crest Conferences
More ....
 Tools for you
Watch Company 
View Company Profile
Company web site
More news from this company
E-Mail Story
Save Story
Search for suppliers of
Kits
Enzymes
Pharmaceutical Processing Equipment
Pharmaceutical Chemicals
Join the forum discussion at:
Hard to Handle
The Factory Floor


Home  |  My ThomasNet News®  |  Industry Market Trends  |  Submit Release  |  Advertise  |  Contact News  |  About Us
Brought to you by Thomasnet.com        Browse ThomasNet Directory

Copyright © 2012 Thomas Publishing Company
Terms of Use - Privacy Policy



Error close

Please enter a valid email address